March 7, 2008 -
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer - 
Abbott (NYSE: ABT) announced that its molecular diagnostics business has entered into an agreement with
Genentech, Inc.,
F. Hoffmann-La Roche Ltd. and
OSI Pharmaceuticals, Inc. to develop a gene test
to potentially assess the clinical benefit of Tarceva® (erlotinib), an oral tablet indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor (EGFR) gene using its proprietary fluorescence in situ hybridization (FISH) technology in NSCLC...
Abbott's Press Release -
